PMC:2940023 / 5660-6460 JSONTXT

{"project":"0_colil","denotations":[{"id":"20559838-2407762-57187","span":{"begin":590,"end":592},"obj":"2407762"}],"text":"Clinical variables and outcome\nAll patients were interviewed at enrollment in the prospective cohort study. Clinical parameters recorded were: age (years), sex (male/female), type of chest pain (atypical vs. typical), body mass index (BMI) (defined as weight/height2 in kg/m2), smoking status (past or current smoker, yes/no), hypertension (present/absent), dyslipidaemia (serum cholesterol \u003e200 mg/dL or 5.18 mmol/L, present/absent), diabetes (plasma glucose ≥126 mg/dL or 7.0 mmol, present/absent) and family history of CAD (present/absent).\nThe CTCS was measured by the Agatston method [15] using dedicated software (syngo Calcium Scoring VE31H, Siemens, Germany). The outcome of interest was the presence of obstructive CAD defined as ≥50% stenosis in at least one vessel (present/absent) on CCA."}

{"project":"2_test","denotations":[{"id":"20559838-2407762-29364889","span":{"begin":590,"end":592},"obj":"2407762"}],"text":"Clinical variables and outcome\nAll patients were interviewed at enrollment in the prospective cohort study. Clinical parameters recorded were: age (years), sex (male/female), type of chest pain (atypical vs. typical), body mass index (BMI) (defined as weight/height2 in kg/m2), smoking status (past or current smoker, yes/no), hypertension (present/absent), dyslipidaemia (serum cholesterol \u003e200 mg/dL or 5.18 mmol/L, present/absent), diabetes (plasma glucose ≥126 mg/dL or 7.0 mmol, present/absent) and family history of CAD (present/absent).\nThe CTCS was measured by the Agatston method [15] using dedicated software (syngo Calcium Scoring VE31H, Siemens, Germany). The outcome of interest was the presence of obstructive CAD defined as ≥50% stenosis in at least one vessel (present/absent) on CCA."}

{"project":"TEST0","denotations":[{"id":"20559838-46-52-57187","span":{"begin":590,"end":592},"obj":"[\"2407762\"]"}],"text":"Clinical variables and outcome\nAll patients were interviewed at enrollment in the prospective cohort study. Clinical parameters recorded were: age (years), sex (male/female), type of chest pain (atypical vs. typical), body mass index (BMI) (defined as weight/height2 in kg/m2), smoking status (past or current smoker, yes/no), hypertension (present/absent), dyslipidaemia (serum cholesterol \u003e200 mg/dL or 5.18 mmol/L, present/absent), diabetes (plasma glucose ≥126 mg/dL or 7.0 mmol, present/absent) and family history of CAD (present/absent).\nThe CTCS was measured by the Agatston method [15] using dedicated software (syngo Calcium Scoring VE31H, Siemens, Germany). The outcome of interest was the presence of obstructive CAD defined as ≥50% stenosis in at least one vessel (present/absent) on CCA."}

{"project":"MyTest","denotations":[{"id":"20559838-2407762-29364889","span":{"begin":590,"end":592},"obj":"2407762"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Clinical variables and outcome\nAll patients were interviewed at enrollment in the prospective cohort study. Clinical parameters recorded were: age (years), sex (male/female), type of chest pain (atypical vs. typical), body mass index (BMI) (defined as weight/height2 in kg/m2), smoking status (past or current smoker, yes/no), hypertension (present/absent), dyslipidaemia (serum cholesterol \u003e200 mg/dL or 5.18 mmol/L, present/absent), diabetes (plasma glucose ≥126 mg/dL or 7.0 mmol, present/absent) and family history of CAD (present/absent).\nThe CTCS was measured by the Agatston method [15] using dedicated software (syngo Calcium Scoring VE31H, Siemens, Germany). The outcome of interest was the presence of obstructive CAD defined as ≥50% stenosis in at least one vessel (present/absent) on CCA."}